Rain Therapeutics to Participate in Piper Sandler's 34th Annual Healthcare Conference
NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandler’s 34th Annual Healthcare Conference, being held November 29 – December 1, 2022, in New York.
Avanish Vellanki, chief executive officer of Rain, will be participating in a fireside chat on Thursday, December 1 at 1:30 p.m. ET. A webcast of the fireside chat can be accessed here. The Company’s management team will participate in on-on-one investor meetings. To request a meeting, please contact your Piper Sandler representative.
About Rain Therapeutics Inc.
Building Business Resilience for MSPs: Cyber Security Best Practices
How IT Can Keep Pace, Part 1 â€“ Data Networks and SD-WAN
Registration Counters Open